Meridith Morgan, Ph.D.
Dr. Morgan received her Ph.D. in Genetics and Developmental Biology in 2002 from West Virginia University. She completed her post-doctoral training in Radiation Biology under the mentorship of Dr. Ted Lawrence at the University of Michigan during which she developed CHK1 inhibitors as chemoradiation sensitizers. In 2009, Dr. Morgan was appointed Assistant Professor of Radiation Oncology at the University of Michigan and continued her research efforts in the fields of the DNA damage response and experimental therapeutic radiation sensitizers. In 2014, Dr. Morgan successfully translated her preclinical laboratory research to a clinical trial in patients with pancreatic cancer. Dr. Morgan runs an NIH-funded laboratory and trains undergraduate, medical and graduate students, as well as post-doctoral and medical fellows.